Catalent CEO John Chiminski
Catalent inks deal with Phathom to make GI drug at recently-renovated Kentucky site
Summer’s over, but New Jersey-based CDMO Catalent had time to squeak in one last deal.
Catalent has signed an agreement to commercially manufacture Phathom Pharmaceuticals’ lead drug, vonoprazan, for the treatment of gastrointestinal diseases. If the drug is approved by the FDA, Catalent will manufacture and package the drug at its large-scale oral solid dose site in Winchester, KY. Phathom has the rights to develop and commercialize vonoprazan in the US, Europe and Canada.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters